BACKGROUND: Between 30% and 60% of clinical cases of hypertrophic cardiomyopathy (HC) can be attributed to mutations in the genes encoding cardiac myofilament proteins. Interestingly, it appears that the likelihood of an underlying myofilament mutation can be predicted by echocardiographic assessment of left ventricular morphology. However, it is not known whether genotypically characterized HC exists as a separate entity with discrete phenotypic morphology and histology or to what extent recognized polymorphisms of the renin-angiotensin-aldosterone system (RAAS) influence this relationship. The presence of cardiac myofilament and mutations and RAAS polymorphisms will have a strong association with the severity of histologic features of HC and characteristic septal shape. METHODS: We conducted a retrospective review of histology specimens, obtained at septal myectomy among 181 patients with medically refractory symptomatic HC. All patients underwent comprehensive genetic analysis for mutations in 8 myofilament-encoding genes; a subset was genotyped for 6 known RAAS-polymorphisms. Patients underwent comprehensive echocardiography by an expert blinded to genotype and microscopic status. RESULTS: Microscopically, severity of myocyte hypertrophy appears to be associated with the presence of recognized HC cardiac myofilament mutations (P = .03). Other histologic features characteristic of HC were not consistently associated with myofilament mutation status. A higher burden of pro-LVH RAAS polymorphisms also appeared to predict only myocyte hypertrophy (P = .01). The presence of RAAS polymorphisms was not associated with the development of a specific septal morphology (P = .6). CONCLUSION: Myofilament-positive HC does not appear to represent a distinct clinical phenotypic entity as evidenced by specific histologic characteristics and septal shape.
BACKGROUND: Between 30% and 60% of clinical cases of hypertrophic cardiomyopathy (HC) can be attributed to mutations in the genes encoding cardiac myofilament proteins. Interestingly, it appears that the likelihood of an underlying myofilament mutation can be predicted by echocardiographic assessment of left ventricular morphology. However, it is not known whether genotypically characterized HC exists as a separate entity with discrete phenotypic morphology and histology or to what extent recognized polymorphisms of the renin-angiotensin-aldosterone system (RAAS) influence this relationship. The presence of cardiac myofilament and mutations and RAAS polymorphisms will have a strong association with the severity of histologic features of HC and characteristic septal shape. METHODS: We conducted a retrospective review of histology specimens, obtained at septal myectomy among 181 patients with medically refractory symptomatic HC. All patients underwent comprehensive genetic analysis for mutations in 8 myofilament-encoding genes; a subset was genotyped for 6 known RAAS-polymorphisms. Patients underwent comprehensive echocardiography by an expert blinded to genotype and microscopic status. RESULTS: Microscopically, severity of myocyte hypertrophy appears to be associated with the presence of recognized HC cardiac myofilament mutations (P = .03). Other histologic features characteristic of HC were not consistently associated with myofilament mutation status. A higher burden of pro-LVH RAAS polymorphisms also appeared to predict only myocyte hypertrophy (P = .01). The presence of RAAS polymorphisms was not associated with the development of a specific septal morphology (P = .6). CONCLUSION: Myofilament-positive HC does not appear to represent a distinct clinical phenotypic entity as evidenced by specific histologic characteristics and septal shape.
Authors: Sara L Van Driest; Michael J Ackerman; Steve R Ommen; Rameen Shakur; Melissa L Will; Rick A Nishimura; A Jamil Tajik; Bernard J Gersh Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Sara L Van Driest; Erik G Ellsworth; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman Journal: Circulation Date: 2003-07-14 Impact factor: 29.690
Authors: Dulce Brito; Pascale Richard; Richard Isnard; João Pipa; Michel Komajda; Hugo Madeira Journal: Rev Port Cardiol Date: 2003-12 Impact factor: 1.374
Authors: Geoffrey T Lamke; Rachel D Allen; William D Edwards; Henry D Tazelaar; Gordon K Danielson Journal: Cardiovasc Pathol Date: 2003 May-Jun Impact factor: 2.185
Authors: Michael J Ackerman; Sara L VanDriest; Steve R Ommen; Melissa L Will; Rick A Nishimura; A Jamil Tajik; Bernard J Gersh Journal: J Am Coll Cardiol Date: 2002-06-19 Impact factor: 24.094
Authors: Polakit Teekakirikul; Seda Eminaga; Okan Toka; Ronny Alcalai; Libin Wang; Hiroko Wakimoto; Matthew Nayor; Tetsuo Konno; Joshua M Gorham; Cordula M Wolf; Jae B Kim; Joachim P Schmitt; Jefferey D Molkentin; Russell A Norris; Andrew M Tager; Stanley R Hoffman; Roger R Markwald; Christine E Seidman; Jonathan G Seidman Journal: J Clin Invest Date: 2010-09-01 Impact factor: 14.808